EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Current and Emerging Therapeutic Approaches in SAPHO Syndrome: A Narrative Review

Florin Liviu Gherghina, Lucian-Mihai Florescu, Claudia Gabriela Ionescu, Alesandra Florescu, Vlad Pădureanu, Virginia Maria Rădulescu, Rodica Pădureanu, Anca Emanuela Mușetescu

Journal of Clinical Medicine · 11.11.2026 · 15 (22) · 8824

DOI: 10.3390/jcm15228824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.11.2026. Verfasst von Florin Liviu Gherghina und 7 weiteren Autor:innen. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a rare inflammatory disorder characterised by heterogeneous osteoarticular and cutaneous manifestations. Its variable clinical presentation, fluctuating disease course, and limited high-quality evidence complicate therapeutic decision-making. This narrative review critically examines established and emerging treatment strategies, with particular emphasis on phenotype-informed management and differences between skeletal and cutaneous responses. A targeted narrative review of the literature was conducted, incorporating clinical studies, observational cohorts, case series, and individual reports addressing therapeutic interventions in SAPHO syndrome. The available evidence was evaluated with consideration of study design, treatment outcomes, follow-up duration, safety, and methodological limitations. Nonsteroidal anti-inflammatory drugs remain the principal initial symptomatic treatment, while intravenous bisphosphonates and tumour necrosis factor inhibitors have the most extensive clinical evidence in persistent osteoarticular disease. Conventional synthetic disease-modifying antirheumatic drugs may be useful in patients with predominant peripheral arthritis. The emerging evidence supports further investigation of interleukin-targeted therapies, Janus kinase inhibitors, and iguratimod, particularly in refractory or mixed phenotypes. However, treatment responses frequently differ between skeletal and cutaneous manifestations, and paradoxical skin reactions may complicate biologic therapy. Most available studies are small, uncontrolled, and heterogeneous, limiting conclusions regarding comparative efficacy and optimal treatment sequencing. SAPHO syndrome requires an individualised, multidisciplinary therapeutic approach guided by the dominant active phenotype, treatment response, and safety considerations. Separate assessment of osteoarticular and cutaneous outcomes is essential. Prospective multicentre studies using standardised outcome measures are needed to establish optimal treatment strategies, long-term efficacy, and safety.

Zitieren

APA

Gherghina, F. L., Florescu, L., Ionescu, C. G., Florescu, A., Pădureanu, V., Rădulescu, V. M., Pădureanu, R., & Mușetescu, A. E. (2026). Current and Emerging Therapeutic Approaches in SAPHO Syndrome: A Narrative Review. Journal of Clinical Medicine, 15(22), 8824. https://doi.org/10.3390/jcm15228824

Vancouver

Gherghina FL, Florescu L, Ionescu CG, Florescu A, Pădureanu V, Rădulescu VM, et al. Current and Emerging Therapeutic Approaches in SAPHO Syndrome: A Narrative Review. Journal of Clinical Medicine. 2026;15(22):8824. doi:10.3390/jcm15228824

BibTeX
@article{Gherghina2026,
  author = {Gherghina, Florin Liviu and Florescu, Lucian-Mihai and Ionescu, Claudia Gabriela and Florescu, Alesandra and Pădureanu, Vlad and Rădulescu, Virginia Maria and Pădureanu, Rodica and Mușetescu, Anca Emanuela},
  title = {Current and Emerging Therapeutic Approaches in SAPHO Syndrome: A Narrative Review},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {8824},
  doi = {10.3390/jcm15228824}
}
Kostenlos starten →